Tumor-Associated Antigens Vector-Encoding Endogenous Dendritic Cells Transduced with Adenovirus Induction of Antitumor Immunity with

Dendritic cells (DCs) are professional Ag-presenting cells that are being considered as potential immunotherapeutic agents to promote host immune responses against tumor Ags. In this study, recombinant adenovirus (Ad) vectors encoding melanoma-associated Ags were used to transduce murine DCs, which were then tested for their ability to activate CTL and induce protective immunity against B16 melanoma tumor cells. Immunization of C57BL/6 mice with DCs transduced with Ad vector encoding the hugp100 melanoma Ag (Ad2/hugp100) elicited the development of gp100-specific CTLs capable of lysing syngeneic fibroblasts transduced with Ad2/hugp100, as well as B16 cells expressing endogenous murine gp100. The induction of gp100-specific CTLs was associated with long term protection against lethal s.c. challenge with B16 cells. It was also possible to induce effective immunity against a murine melanoma self Ag, tyrosinase-related protein-2, using DCs transduced with Ad vector encoding the Ag. The level of antitumor protection achieved was dependent on the dose of DCs and required CD4 1 T cell activity. Importantly, immunization with Ad vector-transduced DCs was not impaired in mice that had been preimmunized against Ad to mimic the immune status of the general human population. Finally, DC-based immunization also afforded partial protection against established B16 tumor cells, and the inhibition of tumor growth was improved by simultaneous immunization against two melanoma-associated Ags as opposed to either one alone. Taken together, these results support the concept of cancer immunotherapy using DCs transduced with Ad vectors encoding tumor-associated Ags. The Journal of Immunology, 1999, 163: 699–707. unlabeled YAC cells successfully prevented lysis of labeled YAC cells without significantly affecting specific lysis of B16 cells. These results indicate that the s.c. and i.v. routes of immunization with transduced DCs elicit equivalent levels of CTL activity against B16 tumor cells.

[1]  J. Mulé,et al.  Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  B. Moss,et al.  gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand , 1998, The Journal of experimental medicine.

[3]  E. Hirschowitz,et al.  Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma , 1998, Gene Therapy.

[4]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[5]  S. Rafii,et al.  Dendritic Cells Genetically Modified with an Adenovirus Vector Encoding the cDNA for a Model Antigen Induce Protective and Therapeutic Antitumor Immunity , 1997, The Journal of experimental medicine.

[6]  D. Kufe,et al.  Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells , 1997, Gene Therapy.

[7]  F. Graham,et al.  Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. , 1997, Human gene therapy.

[8]  M. Bevan,et al.  Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. , 1997, Journal of immunology.

[9]  F. Marincola,et al.  Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[10]  L. Zitvogel,et al.  Bone Marrow‐Derived Dendritic Cells Serve as Potent Adjuvants for Peptide‐Based Antitumor Vaccines , 1997, Stem cells.

[11]  Alan E. Smith,et al.  Effect of the E4 region on the persistence of transgene expression from adenovirus vectors , 1997, Journal of virology.

[12]  S. Rosenberg,et al.  Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma , 1997, The Journal of experimental medicine.

[13]  S. Rosenberg,et al.  Human tumor antigens recognized by T lymphocytes: implications for cancer therapy , 1996, Journal of leukocyte biology.

[14]  H. Sakamoto,et al.  Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines , 1996, The Journal of experimental medicine.

[15]  S. Rosenberg,et al.  Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. , 1996, Journal of immunology.

[16]  L. Zitvogel,et al.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines , 1996, The Journal of experimental medicine.

[17]  L. Zitvogel,et al.  Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.

[18]  G. Prince,et al.  Characterization of an adenovirus gene transfer vector containing an E4 deletion. , 1995, Human gene therapy.

[19]  R. Steinman,et al.  Proliferating dendritic cell progenitors in human blood , 1994, The Journal of experimental medicine.

[20]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  F. Sallusto,et al.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.

[22]  C. Figdor,et al.  Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[23]  P. Coulie,et al.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1993, The Journal of experimental medicine.

[24]  M. Welsh,et al.  Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. , 1993, Human gene therapy.

[25]  R. Steinman,et al.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor , 1992, The Journal of experimental medicine.

[26]  P. Coulie,et al.  Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells , 1992, International journal of cancer.

[27]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[28]  L. Gooding.  Specificities of killing by T lymphocytes generated against syngeneic SV40 transformants: studies employing recombinants within the H-2 complex. , 1979, Journal of immunology.

[29]  P. A. Peterson,et al.  Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. , 1997, Human gene therapy.

[30]  M. Roth,et al.  A comparison of gene transfer methods in human dendritic cells. , 1997, Cancer gene therapy.

[31]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.

[32]  J. Banchereau,et al.  Recent advances in the study of dendritic cells and follicular dendritic cells. , 1995, Immunology today.

[33]  R. Steinman,et al.  Dendritic cells: antigen presentation, accessory function and clinical relevance. , 1993, Advances in experimental medicine and biology.

[34]  R. Steinman,et al.  The dendritic cell system and its role in immunogenicity. , 1991, Annual review of immunology.

[35]  R. Coffman,et al.  Detection of individual mouse splenic T cells producing IFN-gamma and IL-5 using the enzyme-linked immunospot (ELISPOT) assay. , 1990, Journal of immunological methods.

[36]  R. Steinman,et al.  The cell surface of mouse dendritic cells: FACS analyses of dendritic cells from different tissues including thymus. , 1989, Cellular immunology.